Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757879

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757879

Tyrosine Kinase Inhibitors

PUBLISHED:
PAGES: 290 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Tyrosine Kinase Inhibitors Market to Reach US$78.2 Billion by 2030

The global market for Tyrosine Kinase Inhibitors estimated at US$52.9 Billion in the year 2024, is expected to reach US$78.2 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. BCR-ABL, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$40.8 Billion by the end of the analysis period. Growth in the Epidermal Growth Factor Receptor segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.4 Billion While China is Forecast to Grow at 10.9% CAGR

The Tyrosine Kinase Inhibitors market in the U.S. is estimated at US$14.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.5 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global "Tyrosine Kinase Inhibitors" Market - Key Trends & Drivers Summarized

Why Are Tyrosine Kinase Inhibitors Becoming The Cornerstone Of Targeted Cancer Therapy?

The emergence of tyrosine kinase inhibitors (TKIs) has revolutionized cancer treatment by shifting the paradigm from broad-spectrum chemotherapy to precision medicine tailored to molecular targets. These small-molecule drugs work by blocking the activity of tyrosine kinases-enzymes that regulate critical cellular processes including growth, differentiation, and apoptosis. When these enzymes mutate or become overactive, they contribute to the uncontrolled proliferation characteristic of cancers. The discovery of BCR-ABL fusion in chronic myeloid leukemia (CML) and the success of Imatinib, the first FDA-approved TKI, ignited a wave of research and development into similar molecular targets across different cancer types. Today, TKIs are indispensable in the treatment of malignancies like non-small cell lung cancer (NSCLC), gastrointestinal stromal tumors (GIST), renal cell carcinoma, and breast cancer. Their advantage lies in high specificity, oral administration, and improved survival outcomes compared to conventional treatments. As our understanding of oncogenic pathways deepens, the role of TKIs is expanding into combination therapies and adjuvant settings, making them a cornerstone of modern oncology.

How Are Advancements In Genomics And Biomarker Research Fueling TKI Development?

The advancement of genomics and companion diagnostics has significantly enhanced the development and application of TKIs by enabling precise patient selection. Comprehensive genomic profiling allows for the identification of actionable mutations such as EGFR, ALK, ROS1, HER2, and RET, among others. This has led to a surge in FDA approvals of next-generation TKIs designed to target these specific alterations, offering more personalized and effective treatments. For instance, Osimertinib has shown significant efficacy against EGFR-mutated NSCLC, while Alectinib has become the preferred therapy for ALK-positive lung cancers due to its CNS activity and lower toxicity profile. In parallel, the use of liquid biopsies and next-generation sequencing (NGS) is improving real-time monitoring of disease progression and resistance mechanisms. These tools are also fostering the development of adaptive dosing strategies to mitigate side effects while maintaining therapeutic efficacy. Furthermore, novel formulations such as allosteric inhibitors, irreversible binders, and dual-targeted agents are under clinical investigation, aiming to overcome resistance pathways and improve drug penetration in tumor microenvironments.

Could Drug Resistance And Adverse Events Derail The Momentum Of TKI Therapies?

Despite their promise, TKIs are not without limitations-chief among them being acquired resistance and off-target toxicity. Cancer cells often develop secondary mutations or activate alternative signaling pathways, rendering initial TKI treatments ineffective over time. For example, the T790M mutation in EGFR or the gatekeeper mutation in BCR-ABL can compromise first-generation TKIs, necessitating the development of second- and third-generation agents. Additionally, long-term use of TKIs is associated with significant side effects, including hepatotoxicity, cardiotoxicity, and dermatological issues, which can affect patient compliance. The need for continuous molecular monitoring and potential therapy adjustments adds complexity to treatment regimens. Moreover, high treatment costs and limited access in low-resource settings present substantial barriers to widespread adoption. However, ongoing efforts to combine TKIs with immune checkpoint inhibitors, monoclonal antibodies, or chemotherapeutics may help to circumvent resistance and enhance efficacy. There is also a push toward the development of pan-kinase inhibitors that can simultaneously target multiple pathways, thus reducing the likelihood of escape mechanisms and expanding therapeutic indications beyond oncology into areas like inflammatory diseases and fibrosis.

What’s Behind The Sustained Growth In Global Demand For Tyrosine Kinase Inhibitors?

The growth in the tyrosine kinase inhibitors market is driven by several factors shaping clinical practices, research pipelines, and patient expectations. One of the foremost drivers is the increasing global incidence of cancers with identifiable tyrosine kinase mutations, particularly in rapidly urbanizing regions where environmental risk factors are intensifying. Secondly, rising awareness and availability of biomarker-based diagnostics have improved early detection and appropriate therapy alignment, propelling the demand for TKIs as front-line treatment options. On the technological front, robust R&D pipelines from biopharma companies are yielding a steady influx of novel TKIs with improved safety and efficacy profiles, often tailored for rare or previously untreatable mutations. Furthermore, evolving clinical guidelines are incorporating TKIs into earlier lines of therapy and expanding their use in maintenance and neoadjuvant settings. Another key factor is the growing preference for oral, outpatient-administered treatments, which TKIs satisfy, thereby reducing hospitalization costs and improving quality of life for patients. Lastly, expanded insurance coverage and inclusion in national reimbursement lists, especially in countries like China, India, and Brazil, are accelerating market penetration. This combination of epidemiological, clinical, technological, and policy-driven influences is sustaining strong demand across global markets.

SCOPE OF STUDY:

The report analyzes the Tyrosine Kinase Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor, Other Types); Application (Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35935

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tyrosine Kinase Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Propels Demand for Targeted Therapies
    • FDA Breakthrough Therapy Designations Strengthen Business Case for TKIs
    • Expansion of Companion Diagnostics Drives Adoption of Personalized Oncology
    • Growing Investment in Precision Medicine Accelerates Pipeline Growth
    • Favorable Reimbursement Policies in Developed Markets Sustain Uptake
    • Emerging Clinical Evidence Throws the Spotlight on Multi-Target TKIs
    • Increasing Availability of Generic TKIs Expands Patient Access in Developing Markets
    • Technological Advancements in Drug Delivery Spur Innovation in Oral Formulations
    • Strategic Collaborations and Licensing Agreements Propel Market Growth
    • Rising Demand for Minimal Side-Effect Therapies Generates Opportunities
    • Post-Patent Expiry Dynamics Create Competitive Pricing Pressures
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tyrosine Kinase Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for BCR-ABL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for BCR-ABL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for BCR-ABL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Epidermal Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Epidermal Growth Factor Receptor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vascular Endothelial Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vascular Endothelial Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vascular Endothelial Growth Factor Receptor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Chronic Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Renal Cell Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Renal Cell Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Renal Cell Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!